Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma

Clinical Cancer Research

Volumn 15, Issue 13, 2009, Pages 4356-4364

  Nojima, Masanori ^a   Maruyama, Reo ^a,b   Yasui, Hiroshi ^b   Suzuki, Hiromu ^a,b   Maruyama, Yumiko ^b   Tarasawa, Isao ^b   Sasaki, Yasushi ^a   Asaoku, Hideki ^d   Sakai, Hajime ^c   Hayashi, Toshiaki ^b   Mori, Mitsuru ^a   Imai, Kohzoh ^b   Tokino, Takashi ^a   Ishida, Tadao ^b   Toyota, Minoru ^a,b   Shinomura, Yasuhisa ^b  

^a Sapporo Medical University   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

^c TEINE KEIJINKAI HOSPITAL   (Japan)

^d ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DEXAMETHASONE; RAS PROTEIN;

ADVANCED CANCER; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; DNA METHYLATION; DNA MICROARRAY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; EPIGENETICS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE INACTIVATION; GENE INDUCTION; GENE SEQUENCE; GENE SILENCING; GENETIC SCREENING; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; PRIORITY JOURNAL; RASD1 GENE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; AZACITIDINE; CELL LINE, TUMOR; CELL SURVIVAL; DEXAMETHASONE; DNA METHYLATION; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENETIC SCREENING; HUMANS; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RAS PROTEINS;

EID: 67650381828     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3336     Document Type: Article

References (44)

1. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348: 1875- 83.
2. Gehring U, Mohit B,Tomkins GM. Glucocorticoid action on hybrid clones derived from cultured myeloma and lymphoma cell lines. Proc Natl Acad Sci U S A 1972;69:3124 - 7.
3. Smith L, Alexanian R.Treatment strategies for plasma cellmyeloma. CA CancerJClin 1985;35:214-20.
4. HideshimaT, Richardson P, Chauhan D, et al.The proteasome inhibitor PS-341inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6.
5. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons fromthe first decade. Clin Cancer Res 2008;14:1649 - 57.
6. Palumbo A, Gay F, Bringhen S, et al. Bortezomib, doxorubicin and dexamethasone in advancedmultiple myeloma. Ann Oncol 2008;19:1160- 5.
7. Pineda-Roman M, Zangari M, van Rhee F, et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 2008; 22:1419-27.
8. Neri P,Yasui H, HideshimaT, et al. In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells. Br J Haematol 2006;134:37-44.
9. Yasui H, HideshimaT, HamasakiM, et al. SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood 2005; 106:706-12.
10. Yasui H, HideshimaT, Raje N, et al. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res 2005;65:7478-84.
11. Gonzalez D, van der Burg M, Garcia-Sanz R, et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 2007;110: 3112-21.
12. Hideshima T, Bergsagel PL, KuehlWM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104:607-18.
13. De Bruyne E, BosTJ, Asosingh K, et al. Epigenetic silencing of the tetraspanin CD9 during disease progression inmultiple myeloma cells and correlationwith survival. Clin Cancer Res 2008;14:2918-26.
14. Heller G, Schmidt WM, Ziegler B, et al. Genomewide transcriptional response to 5-aza-2¶-deoxycytidine and trichostatin A in multiple myeloma cells. Cancer Res 2008;68:44- 54.
15. Kroeger H, Jelinek J, Estecio MR, et al. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 2008; 112:1366 - 73.
16. Pompeia C, Hodge DR, Plass C, et al. Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1multiple myeloma cell line. Cancer Res 2004;64:3465- 73.
17. Takahashi T, Shivapurkar N, Reddy J, et al. DNA methylation profiles of lymphoid and hematopoietic malignancies. Clin Cancer Res 2004;10:2928-35.
18. Issa JP. DNA methylation as a therapeutic target in cancer. Clin Cancer Res 2007;13:1634-7.
19. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2¶- deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103:1635- 40.
20. OkiY, JelinekJ, Shen L, Kantarjian HM, IssaJP. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood 2008;111:2382-4.
21. Eramo A, Pallini R, Lotti F, et al. Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. Cancer Res 2005;65:11469-77.
22. FojoT, Bates S. Strategies for reversing drug resistance. Oncogene 2003;22:7512-23.
23. Murgo AJ. Innovative approaches to the clinical development of DNA methylation inhibitors as epigenetic remodeling drugs. Semin Oncol 2005;32: 458-64.
24. Satoh A,ToyotaM, Itoh F, et al. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 2003;63:8606-13.
25. Shen L, Kondo Y, Ahmed S, et al. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Res 2007;67: 11335- 43.
26. Kemppainen RJ, Behrend EN. Dexamethasone rapidly induces a novel ras superfamily member-related gene in AtT-20 cells. JBiol Chem1998;273:3129-31.
27. Vaidyanathan G, CismowskiMJ,Wang G,VincentTS, Brown KD, Lanier SM. The Ras-related protein AGS1/ RASD1suppresses cell growth. Oncogene 2004;23: 5858-63.
28. Estecio MR, Gharibyan V, Shen L, et al. LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS ONE 2007;2:e399.
29. Nojima M, Suzuki H,Toyota M, et al. Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene 2007;26:4699-713.
30. Moalli PA, Pillay S,Weiner D, Leikin R, Rosen ST. A mechanism of resistance to glucocorticoids inmultiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA. Blood1992;79:213- 22.
31. Sharma S, Lichtenstein A. Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors. Blood 2008;112:1338-45.
32. Cismowski MJ, Takesono A, Ma C, et al. Genetic screens in yeast to identify mammalian nonreceptor modulators of G-protein signaling. Nat Biotechnol 1999;17:878-83.
33. Takesono A, Cismowski MJ, Ribas C, et al. Receptor-independent activators of heterotrimeric G-protein signaling pathways. JBiol Chem1999;274:33202- 5.
34. Elam C, Hesson L,Vos MD, et al. RRP22 is a farnesylated, nucleolar, Ras-related proteinwith tumor suppressor potential. Cancer Res 2005;65:3117-25.
35. Ellis CA,Vos MD, Howell H,VallecorsaT, Fults DW, Clark GJ. Rig is a novel Ras-related protein and potential neural tumor suppressor. Proc Natl Acad Sci US A 2002;99:9876-81.
36. Yu Y, Xu F, Peng H, et al. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A 1999;96:214 - 9.
37. Furuta J, Nobeyama Y, Umebayashi Y, Otsuka F, Kikuchi K, Ushijima T. Silencing of peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in humanmalignantmelanomas. Cancer Res 2006;66:6080-6.
38. GassonJC, Bourgeois S. A newdeterminant of glucocorticoid sensitivity in lymphoid cell lines. JCellBiol 1983;96:409 - 15.
39. Lindsey JW. Dexamethasone-induced Ras-related protein 1is a potential regulatory protein in B lymphocytes. Int Immunol 2007;19:583-90.
40. Bruick RK. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci US A 2000;97:9082-7.
41. Sandau US, Handa RJ. Glucocorticoids exacerbate hypoxia-induced expression of the pro-apoptotic gene Bnip3 in the developing cortex. Neuroscience 2007;144:482-94.
42. KuboM, HanadaT,Yoshimura A. Suppressors of cytokine signaling and immunity. Nat Immunol 2003;4: 1169 - 76.
43. HeB,You L, UematsuK, et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA 2003;100:14133-8.
44. NiwaY, Kanda H, Shikauchi Y, et al. Methylation silencing of SOCS-3 promotes cell growth andmigration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 2005; 24:6406-17.